
Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says. People treated with durvalumab and chemotherapy were much more likely to go into remission, according to clinical trial results published June 1 in The New England Journal of Medicine. “This is a major step forward… read on > read on >